{
    "info": {
        "nct_id": "NCT05554354",
        "official_title": "Phase 2 Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Inactivating or Inferred Inactivating NF1 Alterations: A ComboMATCH Treatment Trial",
        "inclusion_criteria": "* Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-N2 based on the presence of an actionable mutation as defined in EAY191\n* The patient must be enrolled on the ComboMATCH Master Registration Trial EAY191\n\n  * Note: Patients must fulfill all eligibility criteria outlined in the ComboMATCH Registration Trial EAY191 at the time of registration to EAY191-N2. This includes submission of next-generation sequencing (NGS) data from one of the National Cancer Institute (NCI) credentialed designated laboratories for all potential patients prior to treatment trial assignment. Copy number and allele frequency cutoff as per the Registration protocol\n* Patients must have disease that can be safely biopsied and agree to a pre-treatment biopsy or, if disease cannot be safely biopsied, have archival tissue available from within 12 months prior to the date of registration on the ComboMATCH registration trial (EAY191)\n\n  * Please note the current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trial Support Unit (CTSU) ComboMATCH Registration protocol page\n  * Please note novel/Dynamic aMOI can be submitted for review per the process described in the ComboMATCH Registration protocol\n* A COMBOMATCH TREATMENT TRIAL EAY191-N2 ELIGIBILITY CRITERIA:\n* The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information\n* Age >= 18\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Histologically or cytologically confirmed invasive breast carcinoma\n* Confirmed metastatic disease by either imaging or tissue diagnosis\n* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and one additional lesion that can be biopsied (primary, metastatic both allowed)\n* Patients must have inactivating or inferred inactivating NF1 alterations detected in tumor as determined by the ComboMATCH screening assessment\n* The tumor must have been determined to be estrogen receptor (ER) and/or progesterone receptor (PgR) positive assessed by current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for hormone receptor testing. Patients with >= 1% ER or PgR staining by immunohistochemistry (IHC) are considered positive\n* The tumor must have been determined to be HER2-negative by current ASCO/CAP guidelines\n* Prior use of CDK4/6 inhibitor(i) is required\n* Prior use of fulvestrant regardless of duration is allowed and will determine treatment assignment\n* Up to one line of chemotherapy in metastatic setting is allowed\n* Absolute neutrophil count >= 1,500/mm^3\n* Platelet count >= 100,000/ mm^3\n* Hemoglobin level >= 10 g/dL\n* Creatinine clearance (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula\n* Total bilirubin level =< institutional upper limit of normal\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 5.0 x ULN\n* For patients who will be assigned to Cohort 2 (fulvestrant-resistant), a left ventricular ejection fraction (LVEF) assessment must be performed within 12 weeks prior to registration. The LVEF must be >= 50% regardless of the cardiac imaging facility's lower limit of normal. (LVEF assessment performed by echocardiogram is preferred; however, MUGA scan may be substituted based on institutional/situational preferences)\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial\n* ELIGIBILITY CRITERIA FOR COHORT 1, TREATMENT REGIMEN 2 PATIENTS WHO MIGRATE TO COHORT 2: Cohort migration: Patients treated with control treatment fulvestrant who experience disease progression may be eligible to migrate to Cohort 2 and receive combination treatment with binimetinib and fulvestrant. Patients who choose to do so must meet laboratory values and performance status requirements below and should begin treatment within 28 days\n* PATIENTS WHO MIGRATE TO COHORT 2: Patient's willingness to migrate to Cohort 2 affirmed\n* PATIENTS WHO MIGRATE TO COHORT 2: The patient must have an ECOG performance status of 0-2\n* PATIENTS WHO MIGRATE TO COHORT 2: Absolute neutrophil count >= 1,500/mm^3\n* PATIENTS WHO MIGRATE TO COHORT 2: Platelet count >= 100,000/ mm^3\n* PATIENTS WHO MIGRATE TO COHORT 2: Hemoglobin level >= 10 g/dL\n* PATIENTS WHO MIGRATE TO COHORT 2: Total bilirubin level =< institutional upper limit of normal (ULN)\n* PATIENTS WHO MIGRATE TO COHORT 2: AST and ALT must be =< 5.0 x ULN\n* PATIENTS WHO MIGRATE TO COHORT 2: Creatinine clearance (CrCL) of ≥30 mL/min by the Cockcroft-Gault formula\n* PATIENTS WHO MIGRATE TO COHORT 2: A LVEF performed within the last 3 months must be >= 50% regardless of the cardiac imaging facility's lower limit of normal (LVEF assessment performed by echocardiogram is preferred; however, MUGA scan may be substituted based on institutional/situational preferences)\n* PATIENTS WHO MIGRATE TO COHORT 2: Pregnancy test according to institutional standards must be negative (for patients of childbearing potential only)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Concurrent anticancer therapy\n* Active autoimmune disease requiring systemic treatment within the past 3 months, documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents\n* Active brain metastasis. Brain metastases that have been stable for at least 1 month after completion of treatment are not an exclusion criterion\n* History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment/central serous, chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration\n* Patients will be excluded if they currently have the following risk factors for RVO that are documented prior to the enrollment:\n\n  * Known uncontrolled glaucoma with intra-ocular pressures >= 21 mmHg\n  * Known serum cholesterol >= grade 2.\n  * Known hypertriglyceridemia >= grade 2\n  * Known hyperglycemia (fasting) >= grade 2\n* Patients with baseline QT corrected for heart rate (QTc) > 500 ms, either induced by medication or congenital long QT syndrome will be excluded due to known side effects of binimetinib\n* Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better\n* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications\n* Other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with interpretation of study results\n* Pregnancy or lactation at the time of registration or intention to become pregnant during the study (Note: Pregnancy testing according to institutional standards for patients of childbearing potential)\n\n  * For binimetinib, highly effective contraception should be used for at least 30 days after the last dose, and patients should not breastfeed for 3 days after the last dose\n  * For fulvestrant, highly effective contraception should be used for 1 year after the last dose, and patients should not breastfeed for 1 year after the last dose\n* Use of any investigational product within 30 days prior to study entry\n* INELIGIBILITY CRITERIA FOR COHORT 1, TREATMENT REGIMEN 2 PATIENTS WHO MIGRATE TO COHORT 2\n* PATIENTS WHO MIGRATE TO COHORT 2: Not a candidate for binimetinib in the opinion of the treating investigator",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* ELIGIBILITY CRITERIA FOR COHORT 1, TREATMENT REGIMEN 2 PATIENTS WHO MIGRATE TO COHORT 2: Cohort migration: Patients treated with control treatment fulvestrant who experience disease progression may be eligible to migrate to Cohort 2 and receive combination treatment with binimetinib and fulvestrant. Patients who choose to do so must meet laboratory values and performance status requirements below and should begin treatment within 28 days",
            "criterions": [
                {
                    "exact_snippets": "Patients treated with control treatment fulvestrant who experience disease progression may be eligible to migrate to Cohort 2",
                    "criterion": "prior treatment with fulvestrant",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": "fulvestrant"
                        }
                    ]
                },
                {
                    "exact_snippets": "who experience disease progression",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must meet laboratory values and performance status requirements below",
                    "criterion": "laboratory values",
                    "requirements": [
                        {
                            "requirement_type": "meets protocol-specified laboratory values",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must meet laboratory values and performance status requirements below",
                    "criterion": "performance status",
                    "requirements": [
                        {
                            "requirement_type": "meets protocol-specified performance status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "should begin treatment within 28 days",
                    "criterion": "time to treatment initiation",
                    "requirements": [
                        {
                            "requirement_type": "time from eligibility to treatment initiation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 5.0 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... must be =< 5.0 x ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5.0,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) must be =< 5.0 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5.0,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENTS WHO MIGRATE TO COHORT 2: Creatinine clearance (CrCL) of ≥30 mL/min by the Cockcroft-Gault formula",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance (CrCL) of ≥30 mL/min by the Cockcroft-Gault formula",
                    "criterion": "creatinine clearance (CrCL)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information",
            "criterions": [
                {
                    "exact_snippets": "The patient or a legally authorized representative must provide study-specific informed consent prior to study entry",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for patients treated in the United States (U.S.), authorization permitting release of personal health information",
                    "criterion": "authorization for release of personal health information",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "United States"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The tumor must have been determined to be HER2-negative by current ASCO/CAP guidelines",
            "criterions": [
                {
                    "exact_snippets": "tumor must have been determined to be HER2-negative",
                    "criterion": "tumor HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "by current ASCO/CAP guidelines",
                    "criterion": "HER2 testing method",
                    "requirements": [
                        {
                            "requirement_type": "guideline",
                            "expected_value": "current ASCO/CAP guidelines"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >= 18",
            "criterions": [
                {
                    "exact_snippets": "Age >= 18",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For patients who will be assigned to Cohort 2 (fulvestrant-resistant), a left ventricular ejection fraction (LVEF) assessment must be performed within 12 weeks prior to registration. The LVEF must be >= 50% regardless of the cardiac imaging facility's lower limit of normal. (LVEF assessment performed by echocardiogram is preferred; however, MUGA scan may be substituted based on institutional/situational preferences)",
            "criterions": [
                {
                    "exact_snippets": "a left ventricular ejection fraction (LVEF) assessment must be performed within 12 weeks prior to registration",
                    "criterion": "left ventricular ejection fraction (LVEF) assessment",
                    "requirements": [
                        {
                            "requirement_type": "performed_within_timeframe",
                            "expected_value": "within 12 weeks prior to registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "The LVEF must be >= 50%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Up to one line of chemotherapy in metastatic setting is allowed",
            "criterions": [
                {
                    "exact_snippets": "Up to one line of chemotherapy in metastatic setting is allowed",
                    "criterion": "chemotherapy lines in metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial",
            "criterions": [
                {
                    "exact_snippets": "Patients with a prior or concurrent malignancy",
                    "criterion": "prior or concurrent malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen",
                    "criterion": "potential for malignancy natural history or treatment to interfere with safety or efficacy assessment",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with safety or efficacy assessment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENTS WHO MIGRATE TO COHORT 2: AST and ALT must be =< 5.0 x ULN",
            "criterions": [
                {
                    "exact_snippets": "AST ... must be =< 5.0 x ULN",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5.0,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT must be =< 5.0 x ULN",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5.0,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A COMBOMATCH TREATMENT TRIAL EAY191-N2 ELIGIBILITY CRITERIA:",
            "criterions": [
                {
                    "exact_snippets": "A COMBOMATCH TREATMENT TRIAL EAY191-N2 ELIGIBILITY CRITERIA",
                    "criterion": "enrollment in ComboMATCH Treatment Trial EAY191-N2",
                    "requirements": [
                        {
                            "requirement_type": "enrollment eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >= 100,000/ mm^3",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 100,000/ mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "per mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial",
            "criterions": [
                {
                    "exact_snippets": "Human immunodeficiency virus (HIV)-infected patients",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on effective anti-retroviral therapy",
                    "criterion": "anti-retroviral therapy",
                    "requirements": [
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "undetectable viral load within 6 months of registration",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": "undetectable"
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within 6 months of registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior use of fulvestrant regardless of duration is allowed and will determine treatment assignment",
            "criterions": [
                {
                    "exact_snippets": "Prior use of fulvestrant ... is allowed",
                    "criterion": "prior use of fulvestrant",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior use of fulvestrant ... will determine treatment assignment",
                    "criterion": "treatment assignment",
                    "requirements": [
                        {
                            "requirement_type": "determined by prior use of fulvestrant",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior use of CDK4/6 inhibitor(i) is required",
            "criterions": [
                {
                    "exact_snippets": "Prior use of CDK4/6 inhibitor(i) is required",
                    "criterion": "prior use of CDK4/6 inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENTS WHO MIGRATE TO COHORT 2: Absolute neutrophil count >= 1,500/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count >= 1,500/mm^3",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin level =< institutional upper limit of normal",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin level =< institutional upper limit of normal",
                    "criterion": "total bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "institutional upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula",
                    "criterion": "creatinine clearance (CrCL)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Please note novel/Dynamic aMOI can be submitted for review per the process described in the ComboMATCH Registration protocol",
            "criterions": [
                {
                    "exact_snippets": "novel/Dynamic aMOI can be submitted for review",
                    "criterion": "novel/Dynamic aMOI submission",
                    "requirements": [
                        {
                            "requirement_type": "eligibility for review",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENTS WHO MIGRATE TO COHORT 2: Patient's willingness to migrate to Cohort 2 affirmed",
            "criterions": [
                {
                    "exact_snippets": "Patient's willingness to migrate to Cohort 2 affirmed",
                    "criterion": "willingness to migrate to Cohort 2",
                    "requirements": [
                        {
                            "requirement_type": "affirmation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The patient must be enrolled on the ComboMATCH Master Registration Trial EAY191",
            "criterions": [
                {
                    "exact_snippets": "The patient must be enrolled on the ComboMATCH Master Registration Trial EAY191",
                    "criterion": "enrollment on ComboMATCH Master Registration Trial EAY191",
                    "requirements": [
                        {
                            "requirement_type": "enrollment status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENTS WHO MIGRATE TO COHORT 2: Total bilirubin level =< institutional upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin level =< institutional upper limit of normal (ULN)",
                    "criterion": "total bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed invasive breast carcinoma",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed invasive breast carcinoma",
                    "criterion": "invasive breast carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin level >= 10 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin level >= 10 g/dL",
                    "criterion": "hemoglobin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and one additional lesion that can be biopsied (primary, metastatic both allowed)",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": "measurable by RECIST 1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "one additional lesion that can be biopsied (primary, metastatic both allowed)",
                    "criterion": "biopsiable lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "biopsiable",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have inactivating or inferred inactivating NF1 alterations detected in tumor as determined by the ComboMATCH screening assessment",
            "criterions": [
                {
                    "exact_snippets": "inactivating or inferred inactivating NF1 alterations detected in tumor as determined by the ComboMATCH screening assessment",
                    "criterion": "NF1 alterations in tumor",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "inactivating",
                                "inferred inactivating"
                            ]
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "ComboMATCH screening assessment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENTS WHO MIGRATE TO COHORT 2: Pregnancy test according to institutional standards must be negative (for patients of childbearing potential only)",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy test according to institutional standards must be negative (for patients of childbearing potential only)",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "for patients of childbearing potential only",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The tumor must have been determined to be estrogen receptor (ER) and/or progesterone receptor (PgR) positive assessed by current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for hormone receptor testing. Patients with >= 1% ER or PgR staining by immunohistochemistry (IHC) are considered positive",
            "criterions": [
                {
                    "exact_snippets": "tumor must have been determined to be estrogen receptor (ER) and/or progesterone receptor (PgR) positive",
                    "criterion": "tumor hormone receptor status",
                    "requirements": [
                        {
                            "requirement_type": "estrogen receptor status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "progesterone receptor status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "assessed by current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for hormone receptor testing",
                    "criterion": "hormone receptor testing method",
                    "requirements": [
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "ASCO/CAP guideline recommendations"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with >= 1% ER or PgR staining by immunohistochemistry (IHC) are considered positive",
                    "criterion": "ER or PgR staining by immunohistochemistry (IHC)",
                    "requirements": [
                        {
                            "requirement_type": "staining percentage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Confirmed metastatic disease by either imaging or tissue diagnosis",
            "criterions": [
                {
                    "exact_snippets": "Confirmed metastatic disease",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "by either imaging or tissue diagnosis",
                    "criterion": "metastatic disease confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "imaging",
                                "tissue diagnosis"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count >= 1,500/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count >= 1,500/mm^3",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have disease that can be safely biopsied and agree to a pre-treatment biopsy or, if disease cannot be safely biopsied, have archival tissue available from within 12 months prior to the date of registration on the ComboMATCH registration trial (EAY191)",
            "criterions": [
                {
                    "exact_snippets": "disease that can be safely biopsied",
                    "criterion": "disease biopsy safety",
                    "requirements": [
                        {
                            "requirement_type": "biopsy safety",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agree to a pre-treatment biopsy",
                    "criterion": "agreement to pre-treatment biopsy",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if disease cannot be safely biopsied, have archival tissue available from within 12 months prior to the date of registration",
                    "criterion": "archival tissue availability",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "collection time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": -12,
                                        "unit": "months"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 0,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENTS WHO MIGRATE TO COHORT 2: A LVEF performed within the last 3 months must be >= 50% regardless of the cardiac imaging facility's lower limit of normal (LVEF assessment performed by echocardiogram is preferred; however, MUGA scan may be substituted based on institutional/situational preferences)",
            "criterions": [
                {
                    "exact_snippets": "A LVEF performed within the last 3 months must be >= 50%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "time since assessment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "LVEF assessment performed by echocardiogram is preferred; however, MUGA scan may be substituted",
                    "criterion": "LVEF assessment method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "echocardiogram",
                                "MUGA scan"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENTS WHO MIGRATE TO COHORT 2: The patient must have an ECOG performance status of 0-2",
            "criterions": [
                {
                    "exact_snippets": "The patient must have an ECOG performance status of 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENTS WHO MIGRATE TO COHORT 2: Platelet count >= 100,000/ mm^3",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 100,000/ mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/ mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-N2 based on the presence of an actionable mutation as defined in EAY191",
            "criterions": [
                {
                    "exact_snippets": "Patient must have enrolled onto EAY191",
                    "criterion": "enrollment in EAY191",
                    "requirements": [
                        {
                            "requirement_type": "enrollment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have been given a treatment assignment to ComboMATCH to EAY191-N2",
                    "criterion": "treatment assignment to ComboMATCH EAY191-N2",
                    "requirements": [
                        {
                            "requirement_type": "assignment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "based on the presence of an actionable mutation as defined in EAY191",
                    "criterion": "actionable mutation as defined in EAY191",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Please note the current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trial Support Unit (CTSU) ComboMATCH Registration protocol page",
            "criterions": [
                {
                    "exact_snippets": "current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial",
                    "criterion": "actionable marker of interest (aMOI) or actionable alteration",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENTS WHO MIGRATE TO COHORT 2: Hemoglobin level >= 10 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin level >= 10 g/dL",
                    "criterion": "hemoglobin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Patients must fulfill all eligibility criteria outlined in the ComboMATCH Registration Trial EAY191 at the time of registration to EAY191-N2. This includes submission of next-generation sequencing (NGS) data from one of the National Cancer Institute (NCI) credentialed designated laboratories for all potential patients prior to treatment trial assignment. Copy number and allele frequency cutoff as per the Registration protocol",
            "criterions": [
                {
                    "exact_snippets": "submission of next-generation sequencing (NGS) data from one of the National Cancer Institute (NCI) credentialed designated laboratories for all potential patients prior to treatment trial assignment",
                    "criterion": "NGS data submission",
                    "requirements": [
                        {
                            "requirement_type": "submission",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "laboratory credentialing",
                            "expected_value": "NCI credentialed designated laboratories"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to treatment trial assignment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Copy number and allele frequency cutoff as per the Registration protocol",
                    "criterion": "copy number and allele frequency",
                    "requirements": [
                        {
                            "requirement_type": "cutoff",
                            "expected_value": "as per the Registration protocol"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Known serum cholesterol >= grade 2.",
            "criterions": [
                {
                    "exact_snippets": "Known serum cholesterol >= grade 2",
                    "criterion": "serum cholesterol",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known uncontrolled glaucoma with intra-ocular pressures >= 21 mmHg",
            "criterions": [
                {
                    "exact_snippets": "Known uncontrolled glaucoma",
                    "criterion": "glaucoma",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "intra-ocular pressures >= 21 mmHg",
                    "criterion": "intra-ocular pressure",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "mmHg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hyperglycemia (fasting) >= grade 2",
            "criterions": [
                {
                    "exact_snippets": "Known hyperglycemia (fasting) >= grade 2",
                    "criterion": "fasting hyperglycemia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with baseline QT corrected for heart rate (QTc) > 500 ms, either induced by medication or congenital long QT syndrome will be excluded due to known side effects of binimetinib",
            "criterions": [
                {
                    "exact_snippets": "baseline QT corrected for heart rate (QTc) > 500 ms",
                    "criterion": "QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 500,
                                "unit": "ms"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "congenital long QT syndrome",
                    "criterion": "congenital long QT syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment/central serous, chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration",
            "criterions": [
                {
                    "exact_snippets": "History of ... retinal pathology",
                    "criterion": "retinal pathology",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of retinal pathology on ophthalmologic examination",
                    "criterion": "retinal pathology",
                    "requirements": [
                        {
                            "requirement_type": "evidence_on_ophthalmologic_examination",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "retinal pathology ... that is considered a risk factor for neurosensory retinal detachment/central serous, chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration",
                    "criterion": "retinal pathology as risk factor",
                    "requirements": [
                        {
                            "requirement_type": "risk_factor_for",
                            "expected_value": [
                                "neurosensory retinal detachment",
                                "central serous chorioretinopathy (CSCR)",
                                "retinal vein occlusion (RVO)",
                                "neovascular macular degeneration"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypertriglyceridemia >= grade 2",
            "criterions": [
                {
                    "exact_snippets": "Known hypertriglyceridemia >= grade 2",
                    "criterion": "hypertriglyceridemia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better",
            "criterions": [
                {
                    "exact_snippets": "clinical risk assessment of cardiac function using the New York Heart Association Functional Classification ... patients should be class 2B or better",
                    "criterion": "New York Heart Association Functional Classification",
                    "requirements": [
                        {
                            "requirement_type": "classification",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "B"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENTS WHO MIGRATE TO COHORT 2: Not a candidate for binimetinib in the opinion of the treating investigator",
            "criterions": [
                {
                    "exact_snippets": "Not a candidate for binimetinib in the opinion of the treating investigator",
                    "criterion": "binimetinib candidacy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "investigator opinion",
                            "expected_value": "not a candidate"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of any investigational product within 30 days prior to study entry",
            "criterions": [
                {
                    "exact_snippets": "Use of any investigational product within 30 days prior to study entry",
                    "criterion": "use of investigational product",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2",
            "criterions": [
                {
                    "exact_snippets": "Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2",
                    "criterion": "nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent anticancer therapy",
            "criterions": [
                {
                    "exact_snippets": "Concurrent anticancer therapy",
                    "criterion": "anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications",
            "criterions": [
                {
                    "exact_snippets": "Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug",
                    "criterion": "disease or condition contraindicating investigational drug use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding ... that may affect the interpretation of the results",
                    "criterion": "disease or condition affecting interpretation of results",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding ... that may ... render the patient at high risk from treatment complications",
                    "criterion": "disease or condition rendering patient at high risk from treatment complications",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For fulvestrant, highly effective contraception should be used for 1 year after the last dose, and patients should not breastfeed for 1 year after the last dose",
            "criterions": [
                {
                    "exact_snippets": "For fulvestrant, highly effective contraception should be used for 1 year after the last dose",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration after last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients should not breastfeed for 1 year after the last dose",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "duration after last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* INELIGIBILITY CRITERIA FOR COHORT 1, TREATMENT REGIMEN 2 PATIENTS WHO MIGRATE TO COHORT 2",
            "criterions": [
                {
                    "exact_snippets": "INELIGIBILITY CRITERIA FOR COHORT 1, TREATMENT REGIMEN 2 PATIENTS WHO MIGRATE TO COHORT 2",
                    "criterion": "migration from Cohort 1, Treatment Regimen 2 to Cohort 2",
                    "requirements": [
                        {
                            "requirement_type": "migration status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with interpretation of study results",
            "criterions": [
                {
                    "exact_snippets": "Other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with interpretation of study results",
                    "criterion": "other conditions (as judged by investigator)",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment of exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnancy or lactation at the time of registration or intention to become pregnant during the study (Note: Pregnancy testing according to institutional standards for patients of childbearing potential)",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy ... at the time of registration",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "lactation at the time of registration",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "intention to become pregnant during the study",
                    "criterion": "intention to become pregnant",
                    "requirements": [
                        {
                            "requirement_type": "intention",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Pregnancy testing according to institutional standards for patients of childbearing potential",
                    "criterion": "pregnancy testing",
                    "requirements": [
                        {
                            "requirement_type": "performed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For binimetinib, highly effective contraception should be used for at least 30 days after the last dose, and patients should not breastfeed for 3 days after the last dose",
            "criterions": [
                {
                    "exact_snippets": "highly effective contraception should be used for at least 30 days after the last dose",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration after last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients should not breastfeed for 3 days after the last dose",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "prohibition duration after last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients will be excluded if they currently have the following risk factors for RVO that are documented prior to the enrollment:",
            "criterions": [
                {
                    "exact_snippets": "risk factors for RVO that are documented prior to the enrollment",
                    "criterion": "risk factors for RVO",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation_timeframe",
                            "expected_value": "prior to the enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active brain metastasis. Brain metastases that have been stable for at least 1 month after completion of treatment are not an exclusion criterion",
            "criterions": [
                {
                    "exact_snippets": "Active brain metastasis",
                    "criterion": "brain metastasis",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "Brain metastases that have been stable for at least 1 month after completion of treatment are not an exclusion criterion",
                    "criterion": "brain metastasis",
                    "requirements": [
                        {
                            "requirement_type": "stability duration after treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "month"
                            }
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "stable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease requiring systemic treatment within the past 3 months, documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease requiring systemic treatment within the past 3 months",
                    "criterion": "active autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic treatment within past 3 months",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "documented history of clinically severe autoimmune disease",
                    "criterion": "clinically severe autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "syndrome that requires systemic steroids or immunosuppressive agents",
                    "criterion": "syndrome requiring systemic steroids or immunosuppressive agents",
                    "requirements": [
                        {
                            "requirement_type": "requirement for systemic steroids or immunosuppressive agents",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}